fluorescein ophthalmic (OTC)

Brand and Other Names:BioGlo, Fluorets, more...Ful-Glo
  • Print

Dosing & Uses

AdultPediatric

Dosing Form & Strengths

ophthalmic strips

  • 0.6mg
  • 1mg

solution, injection

  • 10%
  • 25%

Eye Examination

Diagnostic staining

  • Ophthalmic strips are indicated for staining the anterior segment of the eye during eye examinations
  • Moisten by applying 1-2 gtt sterile isotonic irrigation solution, sterile water, or other ophthalmic solution
  • Application: While patient looks down, stroke applicator tip across bulbar conjunctiva for fornix; then have patient blink several time
  • Alternative application methods include having patient close lid tightly over strip until desired amount of staining occurs for exam

Ophthalmic angiography

  • If allergy reaction a possibility, use an intradermal test dose of 0.05 mL; evaluate 30-60 min following intradermal injection; a negative test dose does not exclude potential for allergic reaction; immediate treatment for anaphylaxis, including epinephrine 1:1000 should be available during the procedure
  • Intravenous
    • May administer using a 23 gauge needle attached to small syringe; take steps to ensure needle has not extravasated prior to turning off room light
    • Administer 500 mg as single dose IV into antecubital vein; in cases where a highly sensitive imaging system used (eg, scanning laser ophthalmoscope), may administer a dose of 200 mg; inject dose into antecubital vein over 5-10 sec; luminescence appears 7-30 sec following injection; maintain venous access following procedure in event treatment is needed for anaphylaxis
  • Oral (off-label)
    • Administer 1 g of injection solution orally; clarity of photographs reportedly poorer than photographs obtained following IV administration

Dosing Form & Strengths

ophthalmic strips

  • 0.6mg
  • 1mg

solution, injection

  • 10%
  • 25%

Eye Examination

Diagnostic staining

  • Ophthalmic strips are indicated for staining the anterior segment of the eye during eye examinations
  • Moisten by applying 1-2 gtt sterile isotonic irrigation solution, sterile water, or other ophthalmic solution
  • Application: While patient looks down, stroke applicator tip across bulbar conjunctiva for fornix; then have patient blink several time
  • Alternative application methods include having patient close lid tightly over strip until desired amount of staining occurs for exam

Ophthalmic angiography

  • If allergy reaction a possibility, use an intradermal test dose of 0.05 mL; evaluate 30-60 min following intradermal injection; a negative test dose does not exclude potential for allergic reaction; immediate treatment for anaphylaxis, including epinephrine 1:1000 should be available during the procedure
  • May administer using a 23 gauge needle attached to small syringe; take steps to ensure needle has not extravasated prior to turning off room light
  • Administer 3.5 mg/lb (7.7 mg/kg) as single dose IV into antecubital vein over 5-10 sec; not to exceed 500 mg; luminescence appears 7-30 sec following injection; maintain venous access following procedure in event treatment is needed for anaphylaxis
Next:

Adverse Effects

Frequency Not Defined

Seizure

Dizziness

Headache

Cardiac arrest (rare)

Shock

Hypotension

Syncope

Basilar artery ischemia (rare)

Pruritus GI distress

Skin discoloration (yellow)

Hives

Taste disturbance

Vomiting

Urine discoloration

Dermatitis

Extravasation

Thrombophlebitis

Bronchospasm

Postmarketing reports

Pulmonary edema (acute)

Respiratory arrest

Sickle cell crisis

Localized nerve palsy

Hemolytic anemia

Severe shock and death (rarely)

Previous
Next:

Warnings

Contraindications

Hypersensitivity to components or mercury-containing compounds; history of hypersensitivity to fluorescein sodium

Cautions

Severe local tissue damage, including phlebitis, skin sloughing, toxic neuritis, may occur from extravasation; use caution; discontinue immediately if extravasation occurs

Use caution and monitor closely in patients with history of hypersensitivity, allergies, or asthma

Skin may turn yellow within few minutes of administration and fade in 6-12 hr; urine may appear bright yellow for 24-36 hr

Not for intrathecal or arterial administration

Nausea and/or vomiting and gastrointestinal distress may occur commonly within few minutes following injection; may subside within 10 min

Remove contact lenses before use to avoid staining; after exam, flush eye with saline eye drops and wait at least 1 hr before reinserting contact lenses

Previous
Next:

Pregnancy & Lactation

Pregnancy

There is insufficient data with the use of fluorescein in pregnant women to inform a drug-associated risk

Adequate animal reproduction studies have not been conducted with fluorescein; fluorescein should only be given to a pregnant woman if clearly needed

Animal data

  • Intravenous administration of a single dose of fluorescein to pregnant rats resulted in rapid distribution into the amniotic fluid and fetus

Lactation

Fluorescein injection has been demonstrated to be transferred into human milk for up to 4 days following IV administration

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Indicator dye and diagnostic aid; emits fluorescence when exposed to blue wavelength

Distribution

Vd: 0.5 L/kg

Elimination

Excretion: Urine

Metabolism

Rabidly metabolized to fluorescein monoglucuronide (80%) within 1 hr following IV administration

Previous
Next:

Images

BRAND FORM. UNIT PRICE PILL IMAGE
Ful-Glo ophthalmic (eye)
-
0.6 mg strip
Ful-Glo ophthalmic (eye)
-
1 mg strip
Fluorescite intravenous
-
500 mg/5 mL (10 %) vial
AK-Fluor intravenous
-
500 mg/5 mL (10 %) vial
AK-Fluor intravenous
-
500 mg/2 mL (25 %) vial
BioGlo ophthalmic (eye)
-
1 mg strip
BioGlo ophthalmic (eye)
-
1 mg strip

Copyright © 2010 First DataBank, Inc.

Previous
Next:

Patient Handout

Select a drug:
Patient Education
fluorescein ophthalmic (eye)

NO MONOGRAPH AVAILABLE AT THIS TIME

USES: Consult your pharmacist.

HOW TO USE: Consult your pharmacist.

SIDE EFFECTS: Consult your pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

PRECAUTIONS: Consult your pharmacist.

DRUG INTERACTIONS: Consult your pharmacist.Keep a list of all your medications with you, and share the list with your doctor and pharmacist.

OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.

NOTES: No monograph available at this time.

MISSED DOSE: Consult your pharmacist.

STORAGE: Consult your pharmacist.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

Information last revised July 2016. Copyright(c) 2022 First Databank, Inc.

IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.